Developer docs
API playgroundTry for free, no card

Search company profiles

SinoTau

Full company profile

uuid0002gae

Namestring
SinoTau
Legal namestring
北京先通国际医药科技股份有限公司
Websiteurl
sinotau.com
Company typeenum
Private
Founded yearint
2005
Descriptiontext

SinoTau (先通医药) is a Beijing-headquartered radiopharmaceutical company developing, manufacturing, and commercializing diagnostic and therapeutic radiopharmaceuticals across three therapeutic areas: oncology, neurology (with a focus on Alzheimer's disease diagnostics), and cardiovascular disease. Its commercial portfolio comprises two NMPA-approved products: Florbetaben F18 injection (欧韦宁®), China's first approved Aβ-PET imaging agent for Alzheimer's diagnosis (NMPA approval September 2023), and Adenosine Injection (欧达乐®), China's only domestically-produced cardiac loading drug for myocardial perfusion imaging (NMPA approval January 2023). The company maintains a pipeline of approximately ten innovative radiopharmaceutical assets spanning Phase II through NDA stages, including XTR003 (cardiac, Phase IIb), XTR004 (coronary, Phase III), XTR006/MK-6240 (tau PET, FDA NDA accepted), XTR008 (177Lu-Dotatate, NMPA NDA accepted April 2025), and XTR020 (PSMA PET, Phase III).

The company's technological foundation rests on proprietary radiopharmaceutical formulations and vertically integrated capabilities across five production bases (Beijing HQ, Shanghai R&D, Wuxi, Zhongshan, Mianyang), with a sixth Tianjin facility planned. SinoTau leverages strategic partnerships with global radiopharmaceutical leaders including Blue Earth Diagnostics (PSMA imaging), Life Molecular Imaging (Florbetaben/Neuraceq), Lantheus Holdings (MK-6240 tau imaging), and Isotopia Molecular Imaging (Lutetium-177 supply). The company holds 80+ authorized patents and operates a CRO/CDMO subsidiary (Glotope) to monetize excess manufacturing capacity.

SinoTau operates as a B2B pharmaceutical enterprise selling directly to Chinese hospitals through national and provincial tendering processes, with revenue generated from per-unit drug transactions. Its go-to-market relies on academic promotion teams and medical science liaisons engaging nuclear medicine, neurology, and cardiology departments across China's hospital network. With 400-500+ employees, 2024 revenue of 44.1 million yuan against a net loss of 156 million yuan, and over 2.9 billion yuan in cumulative funding, SinoTau filed for a Hong Kong Stock Exchange listing in June 2025 at a post-IPO valuation of 5.19 billion yuan.

Short descriptiontext

SinoTau is a Beijing-based radiopharmaceutical company developing and commercializing diagnostic and therapeutic radiopharmaceuticals for oncology, neurology, and cardiovascular disease, selling directly to Chinese hospitals via provincial tendering and academic promotion teams.

Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBeijing, China
HQ citystring
Beijing
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
radiopharmaceuticals, nuclear medicine, PET imaging agents, radioligand therapy, molecular imaging
Industry4 codes
PRIMARYHLAIAGAF
Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYEUAKAIAE
Nuclear Medicine Imaging Tracers & PET/SPECT Supply Chain (FDG, Ga-68, logistics/cold chain)
Energy, Utilities & Environment/Nuclear Energy/Nuclear Materials, Radiation Services & Isotopes (Medical/Industrial)
SECONDARYHLAIAJAI
Radiopharmaceutical & Nuclear Medicine Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
  • Scientific Research and Development Services5417
SIC code3 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
  • Medicinal Chemicals & Botanical Products2833
Product category
Radiopharmaceuticals
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Product Sales
TypeOne Time License
Description

Revenue from sale of radiopharmaceutical drugs including adenosine injection, Florbetaben F 18 injection, and other nuclear medicine products. One-time drug transaction model typical of pharmaceutical commercialization in China.

sinotau.com
2In-license Products Commercialization
TypeOne Time License
Description

Commercialization of imported/in-licensed products including Neuraceq and other partnered radiopharmaceuticals through China's hospital supply network.

Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Infrastructure, Supply Chain, Marketing or Sales
Pricing details1 tier
1Hospital supply pricing through national/provincial tendering
ModelOtherBilling cadencePay-as-you-go
Notes

Pharmaceutical products distributed through hospital procurement. Pricing determined through competitive tendering processes in China's healthcare system.

GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

SinoTau (先通医药) develops, manufactures, and commercializes innovative radiopharmaceuticals for precision diagnostics and targeted therapy in oncology, neurology, and cardiovascular disease. The company operates vertically integrated R&D and GMP-certified manufacturing across multiple production bases in China, distributes products through national hospital tendering, and partners with global radiopharmaceutical leaders (Blue Earth Diagnostics, Life Molecular Imaging, Lantheus, Isotopia) for in-licensed products. Two products are commercially launched in China (Florbetaben F18 injection and adenosine injection), with a pipeline of 10+ additional radiopharmaceutical candidates in clinical and regulatory stages.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Post-IPO valuation of 5.19 billion yuan reflects market confidence in pipeline potential and first-mover position in China's radiopharmaceutical sector
+1 more record
Product and service2 records
1欧韦宁® (Florbetaben F18 Injection) / Neuraceq®
CategoryDiagnostic radiopharmaceutical (PET imaging)
Description

18F-labeled PET radiotracer for detection of beta-amyloid plaques in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of dementia; supplied to hospital nuclear medicine departments.

2欧达乐® (Adenosine Injection, 20ml:60mg)
CategoryDiagnostic radiopharmaceutical / cardiac stress agent
Description

Adenosine injection used as a pharmacologic stress agent for myocardial perfusion imaging and echocardiographic drug loading tests in cardiac diagnostic procedures; supplied to hospital cardiology departments through SinoTau's hospital distribution network.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic agreement for development and commercialization of PSMA-targeted PET imaging agent for prostate cancer diagnostics in China. SinoTau leverages partnership for access to proprietary PSMA-targeting technology and global development data.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership for regulatory approval and commercialization of Neuraceq (Florbetaben F 18) in China. Neuraceq received regulatory approval for beta-amyloid PET imaging in Alzheimer's disease diagnosis.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership for XTR006/MK-6240, a next-generation tau protein PET imaging agent for Alzheimer's disease and neurodegenerative disorders. SinoTau licensed Greater China rights for development and commercialization.

Strategic tierCoreTypeTechnology or Integration
Description

Supply agreement for Lutetium-177 (177Lu), a therapeutic radioisotope used in targeted radionuclide therapy. 177Lu supply enables SinoTau's development of radiopharmaceutical therapeutics.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Joint venture for development and commercialization of molecular imaging agents in China, focusing on innovative radiopharmaceutical products for neurological and oncological applications.

Recent move11 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Diversified medical imaging and radiopharmaceutical supplier with PET tracer portfolio; broad incumbent serving the same nuclear medicine departments that SinoTau targets.

TypeDirect peer
Description

U.S. radiopharmaceutical leader (PNT2002, MK-6240 partner) and SinoTau's strategic partner on XTR006; both companies develop and commercialize diagnostic and therapeutic radiopharmaceuticals across oncology and neurology.

TypeDirect peer
Description

World's largest pure-play radiopharmaceutical manufacturer; directly competes with SinoTau in PET/SPECT tracer supply and has scale advantages in global manufacturing and distribution.

4Hengrui Pharmaceuticals
TypeRegional player
Description

Largest Chinese innovative pharmaceutical company that is actively expanding into radiopharmaceuticals; a domestic competitor pursuing overlapping hospital channels and oncology indications.

TypeBroad incumbent
Description

Pharmaceutical major with leading therapeutic radiopharmaceuticals (Pluvicto, Lutathera); represents the major competitive threat in 177Lu-based targeted radionuclide therapy that SinoTau is building toward.

TypeDirect peer
Description

Commercial-stage radiopharmaceutical company with PSMA PET imaging (Illuccix) and pipeline therapeutic assets; directly comparable to SinoTau's PSMA and Lu-177 programs in oncology.

TypeDirect peer
Description

Developer of Florbetaben (Neuraceq) and other neurodegenerative PET tracers; SinoTau's partner on the Florbetaben F18 China program and a comparable player in neurology imaging.

TypeDirect peer
Description

Radiopharmaceutical company specializing in PET imaging agents including PSMA-targeted agents; SinoTau's strategic partner and a direct competitor in the prostate cancer imaging space.

TypeBroad incumbent
Description

Global diagnostic imaging company with a significant radiopharmaceutical portfolio (including through Blue Earth Diagnostics); competes in PET imaging tracers and serves overlapping hospital nuclear medicine customers.

TypeDirect peer
Description

Israeli radiopharmaceutical manufacturer supplying Lu-177 and PET tracers; SinoTau's 177Lu supply partner and a comparable company integrating radioisotope production with finished drug supply.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries6 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors29 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SinoTau

Radiopharmaceuticalssinotau.com

SinoTau is a Beijing-based radiopharmaceutical company developing and commercializing diagnostic and therapeutic radiopharmaceuticals for oncology, neurology, and cardiovascular disease, selling directly to Chinese hospitals via provincial tendering and academic promotion teams.

What SinoTau does

SinoTau (先通医药) is a Beijing-headquartered radiopharmaceutical company developing, manufacturing, and commercializing diagnostic and therapeutic radiopharmaceuticals across three therapeutic areas: oncology, neurology (with a focus on Alzheimer's disease diagnostics), and cardiovascular disease. Its commercial portfolio comprises two NMPA-approved products: Florbetaben F18 injection (欧韦宁®), China's first approved Aβ-PET imaging agent for Alzheimer's diagnosis (NMPA approval September 2023), and Adenosine Injection (欧达乐®), China's only domestically-produced cardiac loading drug for myocardial perfusion imaging (NMPA approval January 2023). The company maintains a pipeline of approximately ten innovative radiopharmaceutical assets spanning Phase II through NDA stages, including XTR003 (cardiac, Phase IIb), XTR004 (coronary, Phase III), XTR006/MK-6240 (tau PET, FDA NDA accepted), XTR008 (177Lu-Dotatate, NMPA NDA accepted April 2025), and XTR020 (PSMA PET, Phase III).

The company's technological foundation rests on proprietary radiopharmaceutical formulations and vertically integrated capabilities across five production bases (Beijing HQ, Shanghai R&D, Wuxi, Zhongshan, Mianyang), with a sixth Tianjin facility planned. SinoTau leverages strategic partnerships with global radiopharmaceutical leaders including Blue Earth Diagnostics (PSMA imaging), Life Molecular Imaging (Florbetaben/Neuraceq), Lantheus Holdings (MK-6240 tau imaging), and Isotopia Molecular Imaging (Lutetium-177 supply). The company holds 80+ authorized patents and operates a CRO/CDMO subsidiary (Glotope) to monetize excess manufacturing capacity.

SinoTau operates as a B2B pharmaceutical enterprise selling directly to Chinese hospitals through national and provincial tendering processes, with revenue generated from per-unit drug transactions. Its go-to-market relies on academic promotion teams and medical science liaisons engaging nuclear medicine, neurology, and cardiology departments across China's hospital network. With 400-500+ employees, 2024 revenue of 44.1 million yuan against a net loss of 156 million yuan, and over 2.9 billion yuan in cumulative funding, SinoTau filed for a Hong Kong Stock Exchange listing in June 2025 at a post-IPO valuation of 5.19 billion yuan.

SinoTau firmographics

Firmographics
Name
SinoTau
Legal name
北京先通国际医药科技股份有限公司
Website
https://sinotau.com
Company type
Private
Founded year
2005
Headcount range
1–10 employees
Short description
SinoTau is a Beijing-based radiopharmaceutical company developing and commercializing diagnostic and therapeutic radiopharmaceuticals for oncology, neurology, and cardiovascular disease, selling directly to Chinese hospitals via provincial tendering and academic promotion teams.
Ownership category
akta.pro rank

SinoTau industry classification

Industry
Product category
Radiopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Scientific Research and Development Services (5417)
SIC
Biological Products, (No Disgnostic Substances) (2836), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAIAGAF
Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYHLAIAGAB
Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYEUAKAIAE
Nuclear Medicine Imaging Tracers & PET/SPECT Supply Chain (FDG, Ga-68, logistics/cold chain)
Energy, Utilities & Environment/Nuclear Energy/Nuclear Materials, Radiation Services & Isotopes (Medical/Industrial)
SECONDARYHLAIAJAI
Radiopharmaceutical & Nuclear Medicine Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling

Keywords

  • Radiopharmaceuticals
  • Nuclear medicine
  • PET imaging agents
  • Radioligand therapy
  • Molecular imaging

Where SinoTau is headquartered

Location

Headquarters

HQ city
Beijing
HQ country
China
HQ region
Asia

Offices6 records

Markets served

SinoTau business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

  1. Pharmaceutical Product Sales: Revenue from sale of radiopharmaceutical drugs including adenosine injection, Florbetaben F 18 injection, and other nuclear medicine products. One-time drug transaction model typical of pharmaceutical commercialization in China.
  2. In-license Products Commercialization: Commercialization of imported/in-licensed products including Neuraceq and other partnered radiopharmaceuticals through China's hospital supply network.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goHospital supply pricing through national/provincial tendering

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

SinoTau product offering

Product offering

Core offering

SinoTau (先通医药) develops, manufactures, and commercializes innovative radiopharmaceuticals for precision diagnostics and targeted therapy in oncology, neurology, and cardiovascular disease. The company operates vertically integrated R&D and GMP-certified manufacturing across multiple production bases in China, distributes products through national hospital tendering, and partners with global radiopharmaceutical leaders (Blue Earth Diagnostics, Life Molecular Imaging, Lantheus, Isotopia) for in-licensed products. Two products are commercially launched in China (Florbetaben F18 injection and adenosine injection), with a pipeline of 10+ additional radiopharmaceutical candidates in clinical and regulatory stages.

Differentiator

Problem solved

Functional benefit

Products and services

  • 欧韦宁® (Florbetaben F18 Injection) / Neuraceq® 18F-labeled PET radiotracer for detection of beta-amyloid plaques in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of dementia; supplied to hospital nuclear medicine departments.
  • 欧达乐® (Adenosine Injection, 20ml:60mg) Adenosine injection used as a pharmacologic stress agent for myocardial perfusion imaging and echocardiographic drug loading tests in cardiac diagnostic procedures; supplied to hospital cardiology departments through SinoTau's hospital distribution network.

Quantifiable outcome

  • Post-IPO valuation of 5.19 billion yuan reflects market confidence in pipeline potential and first-mover position in China's radiopharmaceutical sector
  • +1 more outcomes

Companies that use SinoTau

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

SinoTau technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

SinoTau partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core.

  • Blue Earth DiagnosticscoreStrategic or Co-development PartnerStrategic agreement for development and commercialization of PSMA-targeted PET imaging agent for prostate cancer diagnostics in China. SinoTau leverages partnership for access to proprietary PSMA-targeting technology and global development data.
  • Life Molecular ImagingcoreStrategic or Co-development PartnerPartnership for regulatory approval and commercialization of Neuraceq (Florbetaben F 18) in China. Neuraceq received regulatory approval for beta-amyloid PET imaging in Alzheimer's disease diagnosis.
  • Lantheus HoldingscoreStrategic or Co-development PartnerPartnership for XTR006/MK-6240, a next-generation tau protein PET imaging agent for Alzheimer's disease and neurodegenerative disorders. SinoTau licensed Greater China rights for development and commercialization.
  • Isotopia Molecular ImagingcoreTechnology or IntegrationSupply agreement for Lutetium-177 (177Lu), a therapeutic radioisotope used in targeted radionuclide therapy. 177Lu supply enables SinoTau's development of radiopharmaceutical therapeutics.
  • Cerveau TechnologiescoreStrategic or Co-development PartnerJoint venture for development and commercialization of molecular imaging agents in China, focusing on innovative radiopharmaceutical products for neurological and oncological applications.

Scale indicators9 records

Recent moves11 records

Expansion highlights5 records

SinoTau competitors and assessment

Company assessment

Broad incumbents

  • GE HealthCare: Diversified medical imaging and radiopharmaceutical supplier with PET tracer portfolio; broad incumbent serving the same nuclear medicine departments that SinoTau targets.
  • Novartis: Pharmaceutical major with leading therapeutic radiopharmaceuticals (Pluvicto, Lutathera); represents the major competitive threat in 177Lu-based targeted radionuclide therapy that SinoTau is building toward.
  • Bracco Imaging: Global diagnostic imaging company with a significant radiopharmaceutical portfolio (including through Blue Earth Diagnostics); competes in PET imaging tracers and serves overlapping hospital nuclear medicine customers.

Direct peers

  • Lantheus Holdings: U.S. radiopharmaceutical leader (PNT2002, MK-6240 partner) and SinoTau's strategic partner on XTR006; both companies develop and commercialize diagnostic and therapeutic radiopharmaceuticals across oncology and neurology.
  • Curium Pharma: World's largest pure-play radiopharmaceutical manufacturer; directly competes with SinoTau in PET/SPECT tracer supply and has scale advantages in global manufacturing and distribution.
  • Telix Pharmaceuticals: Commercial-stage radiopharmaceutical company with PSMA PET imaging (Illuccix) and pipeline therapeutic assets; directly comparable to SinoTau's PSMA and Lu-177 programs in oncology.
  • Life Molecular Imaging: Developer of Florbetaben (Neuraceq) and other neurodegenerative PET tracers; SinoTau's partner on the Florbetaben F18 China program and a comparable player in neurology imaging.
  • Blue Earth Diagnostics: Radiopharmaceutical company specializing in PET imaging agents including PSMA-targeted agents; SinoTau's strategic partner and a direct competitor in the prostate cancer imaging space.
  • Isotopia Molecular Imaging: Israeli radiopharmaceutical manufacturer supplying Lu-177 and PET tracers; SinoTau's 177Lu supply partner and a comparable company integrating radioisotope production with finished drug supply.

Regional players

  • Hengrui Pharmaceuticals: Largest Chinese innovative pharmaceutical company that is actively expanding into radiopharmaceuticals; a domestic competitor pursuing overlapping hospital channels and oncology indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

SinoTau financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SinoTau leadership team

Management profile

Number of profiles

Profiles7 records

SinoTau subsidiaries and ownership

Company hierarchy

Subsidiaries6 records

SinoTau funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors29 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SinoTau M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SinoTau

What does SinoTau do?

SinoTau (先通医药) develops, manufactures, and commercializes innovative radiopharmaceuticals for precision diagnostics and targeted therapy in oncology, neurology, and cardiovascular disease. The company operates vertically integrated R&D and GMP-certified manufacturing across multiple production bases in China, distributes products through national hospital tendering, and partners with global radiopharmaceutical leaders (Blue Earth Diagnostics, Life Molecular Imaging, Lantheus, Isotopia) for in-licensed products. Two products are commercially launched in China (Florbetaben F18 injection and adenosine injection), with a pipeline of 10+ additional radiopharmaceutical candidates in clinical and regulatory stages.

Is SinoTau a public or private company?

SinoTau is a private company. It is classified as venture growth investor backed.

When was SinoTau founded?

SinoTau was founded in 2005. It employs 1 to 10 people.

Where is SinoTau based?

SinoTau is headquartered in Beijing, China, in the Asia region.

How does SinoTau make money?

Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are in-license Products Commercialization.

Who are SinoTau's main competitors?

Broad incumbents on record are GE HealthCare, Novartis and Bracco Imaging. Direct peers are Lantheus Holdings, Curium Pharma, Telix Pharmaceuticals, Life Molecular Imaging, Blue Earth Diagnostics and Isotopia Molecular Imaging. Hengrui Pharmaceuticals is listed as a regional player.

Does SinoTau have an API?

No public API is recorded for SinoTau.

What industry is SinoTau in?

SinoTau's product category is Radiopharmaceuticals. Its primary akta.pro industry code is HLAIAGAF, Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish), with a secondary code of HLAIAGAB, Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Dealroom.coHong Kong goes paperless with $57M Sinotau IPO as first digital listing | Dealroom NewsHong Kong's first paperless IPO, Beijing Sinotau International Pharmaceutical Technology, opened books on November 16 for up to $53.9M in H shares, with trading starting November 24. The radiopharmaceutical developer raised net proceeds of $39.8M, and the move launches the Securities and Futures Commission's Uncertificated Securities Market regime, with about 2,700 listed companies transitioning over five years.BenzingaSinotau Aims To Be Hong Kong's 'First Nuclear-medicine Stock'Beijing Sinotau International Pharmaceutical Technology Co. Ltd. filed for an IPO on the Hong Kong Stock Exchange, positioning itself as the first radiopharmaceutical maker to list in Hong Kong. The company, China's first to win regulatory approval for innovative radiopharmaceutical drugs, posted 2024 revenue of 44.10 million yuan against a net loss of 156 million yuan, with its post-investment valuation reaching 5.19 billion yuan after a December pre-IPO funding round. Sinotau has completed at least nine financing rounds since 2017, raising over 2.9 billion yuan combined, and is seeking to capitalize on the global radiopharmaceutical boom sparked by Novartis' record-breaking $1.4 billion Pluvicto sales.Bamboo WorksSinotau aims to become Hong Kong’s ‘first nuclear-medicine stock’Sinotau, China's first company to win regulatory approval for innovative radiopharmaceutical drugs, has filed to list on the Hong Kong Stock Exchange, aiming to become the first nuclear-medicine stock on the exchange; the company recorded a net loss of 156 million yuan in 2024 despite 44.1 million yuan in revenue, with its post-IPO valuation reaching 5.19 billion yuan following multiple funding rounds totaling over 2.9 billion yuan.PR NewswireLife Molecular Imaging and Sinotau Pharmaceutical Group Announce the Regulatory Approval of their Amyloid PET Imaging Radiopharmaceutical Neuraceq® in ChinaLife Molecular Imaging and Sinotau Pharmaceutical Group announced that their amyloid PET imaging radiopharmaceutical Neuraceq® has received regulatory approval from China's National Medical Products Administration. This marks the first time an amyloid-targeting radiotracer has been approved in China, enabling physicians to support Alzheimer's disease diagnosis through visualizing beta-amyloid plaque accumulation. Sinotau will manufacture the drug and distribute it across key provinces, expanding access to state-of-the-art diagnostic technology for cognitive decline evaluation.EqualOceanSinotau Pharmaceutical Technology Raises CNY 320 Mn in Series DBeijing Sinotau Pharmaceutical Technology raised CNY 320 million in a Series D round led by China Kim Kaide and followed by Everest VC, Shandong Longmen, and Deye Capital. The funds will support preclinical and clinical development of radiopharmaceuticals, with four diagnostic and two therapeutic drugs in trials. China's radiopharmaceutical market holds less than 7% of global share, indicating growth potential.